14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYK vs BSX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Boston Scientific Corp. (BSX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas BSX carries 58.8/100 (HOLD) at $43.74 (14.2x Forward P/E, 19.6% operating margin).
Composite vs. Pillar Nuance: While BSX currently prints a higher short-term Unified Composite Score (58.8/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 19.6% operating margin) and revenue trajectory (+7.6% vs. +1.4% YoY).
Technical & Structure Timing Caution: SYK trades in a Neutral technical trend (SURGE options phase, RSI 51.5); meanwhile BSX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment41.7% of Rev ($11.0B)
90D Engineering Disclosures0 Published · Surgical Robotics
BSX Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $64.1B market capitalization and 19.6% operating margin.
OpEx & R&D Reinvestment48.4% of Rev ($10.2B)
90D Engineering Disclosures0 Published
Investor FAQ SYK vs BSX Key Questions & Quantitative Answers
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Boston Scientific Corp. (BSX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas BSX carries 58.8/100 (HOLD) at $43.74 (14.2x Forward P/E, 19.6% operating margin). Composite vs. Pillar Nuance: While BSX currently prints a higher short-term Unified Composite Score (58.8/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 19.6% operating margin) and revenue trajectory (+7.6% vs. +1.4% YoY). Technical & Structure Timing Caution: SYK trades in a Neutral technical trend (SURGE options phase, RSI 51.5); meanwhile BSX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SYK leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with BSX at +1.4% YoY revenue growth and -21.5% YoY earnings growth on $21.1B TTM revenue (68.0% gross margin, 19.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while BSX shifted +104.4%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 48.4% of Rev ($10.2B) (0 disclosures) for BSX.
BSX screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas BSX trades at 14.2x Forward P/E, 18.6x Trailing P/E, 0.76x PEG, and 3.6x EV/Revenue (6.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus BSX (14.1% ROE) capital efficiency.
In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, BSX carries 77.2% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 1.01x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.